Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 2446 • ACR Convergence 2024
Nailfold Videocapillaroscopy Findings in Patients with Limited Cutaneous versus Diffuse Cutaneous Systemic Sclerosis: The First Detailed Retrospective Study
Ana Margarida Correia¹, Rosanna Campitiello², Emanuele Gotelli³, Carmen Pizzorni⁴, Alberto Sulli⁵, vanessa smith⁶ and Maurizio Cutolo³, ¹Hospital de Braga, Unidade Local de Saúde de Braga, Braga, Portugal, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Liguria, Italy, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by microvascular damage, immune system activation and fibrosis. Clinical phenotypes are defined according to skin…
Abstract Number: 2468 • ACR Convergence 2024
Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease
Cristina Padilla¹, Veena Katikineni², Yongseok Park¹, Leigh Freno³, Maureen Laffoon⁴ and Robyn Domsic⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Providence, Victorville, CA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is characterized as episodic color changes of the digits occurring with exposure to cold environments, sudden temperature decreases, and emotional stress. …
Abstract Number: 2469 • ACR Convergence 2024
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Stefano Di Donato¹, Vishal Kakkar², Silvia Bellando-Randone³, Marco Matucci-Cerinic⁴ and Francesco Del Galdo², and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
Abstract Number: 2471 • ACR Convergence 2024
Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis
Namitha Nair¹, Thomas Medsger, Jr², Robert Lafyatis³, Maureen Laffoon⁴, Leigh Freno⁴ and Robyn Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
Abstract Number: 2472 • ACR Convergence 2024
Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?
Andrea Alvear-Torres¹, María José Martínez-Becerra², María Carmen Vegas-Sánchez³, Sheila Recuero-Díaz¹, María Pérez-ferro⁴ and Olga Sánchez-Pernaute⁵, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Department of Immunology. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ⁴Department of Rheumatology. Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁵Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Anti-centromere (aCENP) antibodies are considered highly specific of systemic sclerosis (SSc), typically defining a limited cutaneous phenotype, usually associated to Raynaud´s phenomenon (RP). It…
Abstract Number: 2683 • ACR Convergence 2024
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Pavel Nikitin¹, Harshdeep Chawla¹, Manmohan Singh¹, Samuel Theodore², Salavat Aglyamov¹, Meng Zhang², Brian Skaug², Maureen Mayes², Kirill Larin¹ and Shervin Assassi², ¹University of Houston, Houston, TX, ²UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Joseph Washington, Cencora, Washington, DC
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
Abstract Number: 0677 • ACR Convergence 2024
Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Gulsen Ozen¹, Sofia Pedro², Kaleb Michaud³ and Robyn Domsic⁴, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…
Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Rachel Wallwork¹, Haomin Hu², Ami Shah³, Laura Hummers⁴, John Pauling⁵, Victoria Flower⁶, Bambang Parmanto², Andi Saptono² and Robyn Domsic⁷, ¹Johns Hopkins University, Towson, MD, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…
Abstract Number: 1956 • ACR Convergence 2024
Artificial Intelligence Enhanced Analysis of Nailfold Capillaries by Dermatoscopy in Rheumatology Centers
Genessis Maldonado¹, Eduardo Ramos-ibañez², Borja del Carmelo Gracia-Tello³, Radic Mislav⁴ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Zaragoza, Zaragoza, Spain, ³Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁴University Hospital of Split, Split, Croatia
Background/Purpose: The use of dermatoscopes in rheumatology has been established for several years. However, the application of artificial intelligence for the detection of abnormalities in…
Abstract Number: 2069 • ACR Convergence 2024
Cancer Risk and Screening Effectiveness in Idiopathic Inflammatory Myopathy: Validating IMACS Guidelines in a Retrospective Indian Cohort
Lovely Kumari¹, VISHNU KONERU², subin Philip¹, sai Kumar Dunga³, Mamatha gorijavulu⁴, Aishwarya Gopal⁵, Christina Mariaselvam⁶, Molly Thabah⁷, Vir Singh Negi⁸ and Chengappa Kavadichanda⁹, ¹JIPMER,PUDUCHERRY, PUDUCHERRY, Puducherry, India, ²JIPMER,PUDUCHERRY, PUDUCHERRY, India, ³JIPMER,PUDUCHERRY, VIZAG, Andhra Pradesh, India, ⁴JIPMER,PUDUCHERRY, HYDERABAD, Andhra Pradesh, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁶JIPMER, Puducherry, Puducherry, India, ⁷Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁸AIIMS BILASPUR, BILASPUR, Himachal Pradesh, India, ⁹Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India
Background/Purpose: Idiopathic inflammatory myopathy (IIM) carries an elevated cancer risk. The International Myositis Assessment and Clinical Studies Group (IMACS) has issued evidence-based guidelines for cancer…
Abstract Number: 2442 • ACR Convergence 2024
Clustering Algorithm as an Exploratory Analysis of Different Clinical Phenotypes in Systemic Sclerosis. Data from the PRECISESADS Study
Santiago Dans Caballero¹, Clementina López Medina², Chary Lopez-Pedrera³, Carlos Perez-Sanchez⁴, Alejandro Escudero-Contreras⁵ and Rafaela Ortega-Castro⁶, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Reina Sofia University Hospital, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Reina Sofia University Hospital, Córdoba, Spain, ⁶Hospital Reina Sofía, Cordoba, Andalucia, Spain
Background/Purpose: Systemic sclerosis is a systemic autoimmune disease with multiorgan involvement. Its pathophysiology is based on three pillars: vasculopathy, fibrosis, and autoimmunity. Despite advances in…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].